Clinical Trial Update: A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating SRA737 in combination with gemcitabine with or without cisplatin in patients with advanced solid tumors; study status completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• CISPLATIN (cisplatin)
• Gemcitabine (Gemcitabine)
• SRA737 (SRA737)

Snippet

Sponsor: Sierra Oncology LLC - a GSK company | Conditions: Advanced Solid Tumors | Phase 1, Phase 2 | Status: COMPLETED